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Lactoferrin (Lf) is one of the antigens of antineutrophil cytoplasmic antibodies (ANCA) 
and functions as an endogenous suppressor of neutrophil extracellular trap (NET) for-
mation. However, the prevalence and pathogenicity of anti-lactoferrin antibodies (aLf) 
in ANCA-associated vasculitis (AAV) remain unrevealed. This study aimed to examine 
the significance of aLf in AAV, initially. Sixty-five sera from AAV patients, including 41 
microscopic polyangiitis, 5 granulomatosis with polyangiitis, and 19 eosinophilic gran-
ulomatosis with polyangiitis (EGPA) patients, were subjected to aLf detection using 
enzyme-linked immunosorbent assay. Clinical characteristics were compared between 
aLf-positive and aLf-negative patients. Neutrophils from healthy donors were exposed to 
suboptimal dose (10 nM) of phorbol myristate acetate (PMA) with aLf followed by eval-
uation of NET formation. Results demonstrated that 4 out of 65 AAV sera (6.2%) were 
positive for aLf. All of them were EGPA sera (4/19, 21.1%). In EGPA, the frequency of 
renal involvement, serum CRP levels, and Birmingham Vasculitis Activity Score (BVAS) in 
the aLf-positive patients was significantly higher than those in the aLf-negative patients, 
and the aLf titer correlated positively with the serum CRP level and BVAS. The NET 
formation was particularly enhanced by combined stimulation of 10 nM PMA and 1 µg/
mL aLf. IgG isolated from sera of the aLf-positive EGPA patients (250 µg/mL) enhanced 
NET formation induced by 10 nM of PMA, and the effect was abolished completely by 
absorption of the aLf. This pilot study suggests that aLf enhance NET formation induced 
by PMA and are associated with disease activity of EGPA.
Keywords: lactoferrin, anti-lactoferrin antibody, neutrophil, neutrophil extracellular trap, eosinophilic 
granulomatosis with polyangiitis
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inTrODUcTiOn
Antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) is characterized by pauci-immune necrotizing 
small vessel vasculitis with the presence of ANCA in the serum. 
AAV includes microscopic polyangiitis (MPA), granulomatosis 
with polyangiitis (GPA), and eosinophilic granulomatosis with 
polyangiitis (EGPA) (1). The major target antigens of ANCA 
are myeloperoxidase (MPO) and proteinase 3 (PR3). In MPA, 
the renal glomeruli are affected preferentially and the majority 
of the patients are positive for MPO–ANCA. Inflammation 
that is not centered on small vessels, including granulomatous 
inflammation, is generally absent. On the contrary, GPA displays 
necrotizing granulomatous inflammation that usually involves 
the respiratory tract and simultaneously develops necrotizing 
small vessel vasculitis. Pauci-immune type necrotizing crescen-
tic glomerulonephritis is common in GPA, as well as in MPA. 
Typically, GPA patients are positive for PR3-ANCA. EGPA is 
an eosinophil-rich and necrotizing granulomatous vasculitis 
that affects predominantly small- to medium-sized vessels. 
This disease is associated with asthma or allergic sinusitis. The 
prominence of eosinophils in the blood and affected tissues is 
an essential feature of this disease. Approximately half of EGPA 
patients are positive for MPO–ANCA.
Lactoferrin (Lf) is present in specific granules of neutrophils 
(2). It may represent a target for ANCA in patients with autoim-
mune connective tissue diseases, such as arthritis and systemic 
lupus erythematosus (3, 4). Although earlier studies have 
demonstrated that lupus patients with anti-lactoferrin antibod-
ies (aLf) exhibit higher disease activity than those without aLf 
(5, 6), the prevalence and pathogenicity of aLf in AAV remain 
unrevealed.
Lactoferrin is immediately secreted by degranulation upon 
activation of neutrophils (7). Recently, Okubo et al. have reported 
that Lf could play a role as an endogenous suppressor for neutro-
phil extracellular trap (NET) formation in activated and dying 
neutrophils (8). NETs are composed of extracellularly spreading 
chromatin fibers and neutrophil intracellular granule proteins, 
such as MPO and PR3 (9). Accumulating evidence indicates that 
excessive NET formation is involved in the pathogenesis of AAV 
(10–16).
In the present study, sera from AAV patients and healthy 
controls were subjected to aLf detection in order to examine the 
prevalence of aLf in AAV. We investigated correlations between 
the titers of aLf and clinical parameters. Furthermore, we deter-
mined the contribution of aLf to NET formation.
MaTerials anD MeThODs
Patients and serum samples
In order to examine the prevalence and pathogenicity of aLf 
in AAV initially, 65 AAV patients including 41 MPA, 5 GPA, 
and 19 EGPA patients, who were diagnosed and treated at the 
Department of Internal Medicine II, Hokkaido University 
Hospital or Department of Dermatology, St. Marianna University 
Hospital from January 2005 to April 2014, were enrolled in this 
study. For controls, 10 healthy volunteers were included. Because 
this is a pilot exploratory study, a random study population size 
was chosen. After acquirement of written informed consent, 
peripheral blood was obtained without anticoagulants, and 
the sera were stored at −80°C until use. Clinical information, 
including age and gender, laboratory data, such as serum levels 
of MPO–ANCA and CRP, and Birmingham Vasculitis Activity 
Score (BVAS) of the AAV patients at the point of blood sampling 
were collected from medical records retrospectively. The his-
tory of asthma and eosinophil count in the peripheral blood 
were also collected concerning EGPA patients. This study was 
approved for practice by our Institutional Ethical Committee, the 
Ethical Committee of the Faculty of Health Sciences, Hokkaido 
University (Permission No. 15-90).
Quantification of anti-lf antibodies
Titer of aLf was determined using the enzyme-linked immuno-
sorbent assay (ELISA) kit (Orgentec Diagnostika GmBH, Mainz, 
Germany).
isolation of neutrophils
Human neutrophils were obtained from 20  mL of peripheral 
blood of healthy volunteers by density centrifugation using 
Polymorph Prep (Axis-Shield, Dundee, Scotland). After washing 
with PBS, the obtained cells were resuspended in RPMI 1640 
medium supplemented with 5% fetal bovine serum.
reagents
For in  vitro assay, rabbit polyclonal anti-human Lf antibodies 
(CSB-PA00870EORb) (Cusabio Biotech, Hubei, China) and rab-
bit control IgG (Beckman Coulter, Tokyo, Japan) were employed. 
Prior to use, the contaminating endotoxin was removed using 
ProteoSpin Endotoxin Removal Micro Kit (Norgentic Biotech, 
ON, Canada). Residual endotoxin was ruled out using Limulus 
Color KY Test Kit (Wako Pure Chemical, Osaka, Japan). Phorbol 
myristate acetate (PMA) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).
neT induction assay
Peripheral blood neutrophils obtained from healthy volunteers 
were seeded on chamber slides (1  ×  105/mL), incubated for 
15 min at 37°C, and then exposed to 0 or 10 nM PMA combined 
with 1  µg/mL aLf (CSB-PA00870EORb) or control rabbit IgG. 
After incubation for 3  h at 37°C, the samples were fixed with 
4% paraformaldehyde (PFA) followed by mounting with the 
solution containing 4′,6-diamidino-2-phenylindole (DAPI) 
(Sigma-Aldrich). NET area was represented by DAPI-positive 
area, which was calculated using Image J software, as described 
previously (12, 17).
isolation of igg from serum
IgG was isolated from sera using an immunoadsorbent col-
umn (Protein G HP SpinTrap) (GE healthcare, Tokyo, Japan). 
Contamination by endotoxin in the IgG samples was ruled out 
using the endotoxin detection kit.
FigUre 1 | serum levels of alf in anti-neutrophil cytoplasmic 
antibodies-associated vasculitis patients and healthy controls. Titer 
of anti-lactoferrin antibodies was determined using the enzyme-linked 
immunosorbent assay kit. Cutoff value of the kit is represented by a broken 
line (10 units/mL).
Table 1 | Demographics of antineutrophil cytoplasmic antibodies 











Age, years, mean (SD) 69.5 (11.0) 47.8 (6.10) 54.6 (12.6)
Female, n (%) 24 (58.5%) 5 (100%) 13 (68.4%)
Myeloperoxidase–ANCA 
positive, n (%)
27 (65.9%) 0 (0%) 7 (36.8%)
CRP, mg/dL, mean (SD) 7.69 (5.63) 6.71 (3.94) 3.20 (4.19)
Birmingham Vasculitis 
Activity Score, mean (SD)
13.9 (8.03) 17.7 (9.12) 17.6 (11.4)
Table 2 | comparison of clinical characteristics of eosinophilic 






Age, years, mean (SD) 56.6 (3.33) 54.0 (13.7) n.s.a
Female, n (%) 3 (75.0%) 10 (66.7%) n.s.b
Asthma, month, mean (SD) 27.8 (16.6) 42.6 (24.0) n.s.a
Eosinophil count/μL, mean (SD) 12,500 (8,170) 7,420 (4,400) n.s.a
MPO–ANCA positive, n (%) 3 (75.0%) 4 (26.7%) n.s.b
CRP, mg/dL, mean (SD) 8.89 (4.44) 1.68 (0.96) p < 0.001a
BVAS, mean (SD) 29.8 (5.97) 14.5 (12.0) p < 0.01a
aStudent’s t-test.
bFisher’s exact test.
n.s., not significant; BVAS, Birmingham Vasculitis Activity Score; aLf, anti-lactoferrin 
antibodies; MPO, myeloperoxidase; ANCA, anti-neutrophil cytoplasmic antibodies.
FigUre 2 | correlation of anti-lactoferrin antibodies titer with serum 
crP level (a) and birmingham Vasculitis activity score (b) in 
eosinophilic granulomatosis with polyangiitis patients (n = 19).
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absorption of alf in serum
Recombinant human Lf (10 µg) (Hölzel Diagnostika, Cologne, 
Germany) was added to 500  µL patient sera. After incubation 
for 15  min at room temperature, IgG was purified using the 
immunoadsorbent column. The absorption of aLf was confirmed 
using WIESLAB ANCA Panel Kit (Euro Diagnostica, Malmö, 
Sweden). Residual Lf was confirmed as below the detection limit 
in Lf ELISA Kit (Assaypro, St. Charles, MO, USA).
neT induction by Patient igg before  
and after absorption of alf
Peripheral blood neutrophils obtained from healthy volunteers 
were seeded on chamber slides (1 × 105/mL), incubated for 15 min 
at 37°C, and then exposed to 0 or 10 nM PMA combined with 
250  µg/mL patient IgG (before and after absorption of aLf) or 
healthy control IgG. After incubation for 3 h at 37°C, the samples 
were fixed with 4% PFA followed by mounting with a solution 
containing DAPI. NET area was represented by DAPI-positive 
area, which was calculated using Image J software.
statistical analysis
Data of in vitro assay were obtained from experiments repeated 
five times and presented as mean ± SD values. Paired or unpaired 
Student’s t-tests, Mann–Whitney U-tests, one-way ANOVA, and 
Fisher’s exact test were applied appropriately for statistical evalu-
ation with GraphPad Prism 5.0 software. p-values of less than 0.05 
were regarded as statistically significant.
FigUre 3 | neT induction assay. Peripheral blood neutrophils obtained from healthy volunteers were seeded on chamber slides (1 × 105/mL), incubated for 
15 min at 37°C, and then exposed to 0 or 10 nM phorbol myristate acetate (PMA) combined with 1 µg/mL aLf (CSB-PA00870EORb) or control rabbit IgG. After 
incubation for 3 h at 37°C, the samples were fixed with 4% paraformaldehyde followed by mounting with a solution containing DAPI. For positive control, the 
neutrophils were exposed to 100 nM PMA for 3 h at 37°C. (a) The representative photomicrographs are shown (original magnification: ×200). (b) NET area was 
represented by DAPI-positive area, which was calculated using Image J software. Data were presented as mean ± SD values of relative NET induction in which the 
value of the positive control (PMA 100 nM) was set as 1. Experiments were repeated five times. **p < 0.01.
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resUlTs
anti-lf antibodies in aaV Patients
Sixty-five AAV patients, including 41 MPA, 5 GPA, and 19 
EGPA patients, were enrolled in this study. The demographics 
are summarized in Table 1. Serum titer of aLf was determined 
in the AAV patients (n = 65) and healthy volunteers (n = 10) 
(Figure  1). Cutoff value of the ELISA kit used for this assay 
is 10 units/mL. Four out of 65 AAV sera (6.2%) were positive 
for aLf, whereas none of the sera from healthy volunteers was 
aLf-positive (0%). All of the aLf-positive sera were obtained 
from EGPA patients. The aLf-positive rate in EGPA was 21.1% 
(4/19).
comparison of clinical characteristics  
of egPa with or without alf
The differences in clinical characteristics of EGPA patients with 
or without aLf were determined. Although age, gender, history 
of asthma, eosinophil count in the peripheral blood, and positive 
rate of MPO–ANCA were equivalent among the EGPA patients 
regardless of the presence of aLf, the serum CRP levels and BVAS 
in the aLf-positive EGPA patients (n = 4) were significantly higher 
than those in the aLf-negative EGPA patients (n = 15) (Table 2). 
Correspondingly, the aLf titer showed positive correlation with 
the serum CRP level (r = 0.55, p < 0.05) and BVAS (r = 0.67, 
p < 0.01) (Figure 2). These findings indicate that the aLf titer is 
associated with disease activity of EGPA.
FigUre 4 | neutrophil extracellular trap (neT) induction by patient 
igg before and after absorption of anti-lactoferrin antibodies (alf). For 
this purpose, eosinophilic granulomatosis with polyangiitis sera with aLf were 
divided into the following two groups; Group 1, aLf-positive/myeloperoxidase 
(MPO)–anti-neutrophil cytoplasmic antibodies (ANCA)-negative (n = 1) and 
Group 2, aLf-positive/MPO–ANCA-positive (n = 3). Sera from a healthy 
volunteer and from microscopic polyangiitis patients (Group 3, aLf-negative/
MPO–ANCA-positive, n = 3) were used as controls. Peripheral blood 
neutrophils obtained from healthy volunteers were seeded on chamber slides 
(1 × 105/mL), incubated for 15 min at 37°C, and then exposed to 0 or 10 nM 
phorbol myristate acetate (PMA) combined with 250 µg/mL patient IgG 
(before and after absorption of aLf) or healthy control IgG. After incubation for 
3 h at 37°C, the samples were fixed with 4% paraformaldehyde followed by 
mounting with the solution containing DAPI. For positive control, the 
neutrophils were exposed to 100 nM PMA for 3 h at 37°C. NET area was 
represented by DAPI-positive area, which was calculated using Image J 
software. Data were presented as mean ± SD values of relative NET 
induction in which the value of the positive control (PMA 100 nM) was 
set as 1. Experiments were repeated five times. *p < 0.05.
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anti-lf antibodies enhance neT 
Formation induced by PMa
Since Lf was shown to function as an endogenous suppressor for 
NET formation, we hypothesized that aLf could interfere with the 
inhibitory role of Lf and result in enhancement of NET formation 
induced by PMA. Thus, the influence of aLf on NET formation was 
determined in vitro. Although aLf alone (1 µg/mL) did not induce 
NET formation in neutrophils (1 × 105/mL), the aLf enhanced 
NET formation when combined with a suboptimal dose (10 nM) 
of PMA (Figure 3A). Repeated experiments demonstrated that 
the effect was statistically significant (Figure 3B).
anti-lf antibodies in egPa sera enhance 
neT Formation induced by PMa
Next, we examined if aLf in EGPA sera could enhance NET 
formation induced by PMA as well. For this purpose, EGPA 
sera with aLf were divided into the following two groups; Group 
1, aLf-positive/MPO–ANCA-negative (n  =  1) and Group 2, 
aLf-positive/MPO–ANCA-positive (n = 3). Sera from a healthy 
volunteer and from MPA patients (Group 3, aLf-negative/
MPO–ANCA-positive, n = 3) were used as controls. As shown 
in Figure  4, IgG isolated from EGPA sera with aLf (250  µg/
mL) enhanced NET formation induced by the suboptimal dose 
(10 nM) of PMA regardless of the presence of MPO–ANCA (both 
in Group 1 and Group 2). Moreover, this effect was abolished 
completely by absorption of aLf using recombinant Lf (both in 
Group 1 and Group 2). On the contrary, IgG eluted from MPA 
sera with MPO–ANCA but without aLf (Group 3) did not exhibit 
the enhancement. The collective findings suggest that aLf in 
EGPA sera contribute to enhanced NET formation when some 
stimuli, which mimic PMA, act on neutrophils in vivo.
DiscUssiOn
In the present study, we have demonstrated that some EGPA 
patients have aLf in the serum, and that the aLf titer is correlated 
with the disease activity. Furthermore, we have demonstrated that 
aLf (not only commercially available polyclonal antibodies but 
also those in EGPA sera) can enhance NET formation induced 
by a suboptimal dose of PMA in vitro. This is the first evidence 
that focuses on the significance of aLf in AAV, especially in EGPA.
The stimulation with aLf alone (1 µg/mL) did not induce NET 
formation in neutrophils (1 × 105/mL). This finding is consistent 
with the presence of Lf in the specific granules of neutrophils 
under unstimulated conditions (2). On the contrary, the combined 
stimulation with aLf (1 µg/mL) and a suboptimal dose (10 nM) 
of PMA enhanced significantly in  vitro NET formation. It has 
been shown that Lf was immediately secreted by degranulation 
upon activation of neutrophils (7). More recently, Okubo et al. 
demonstrated that Lf suppressed NET formation through charge-
dependent interaction with the chromatin fibers in netting neu-
trophils (8). The Lf secreted by 10 nM PMA is considered to be 
sufficient for the inhibition of the NET induction force of 10 nM 
PMA so that the dose of PMA is suboptimal. We hypothesize that, 
when aLf is present, it could cancel out the endogenous suppres-
sor effect of Lf, resulting in the enhancement of NET formation 
even under the suboptimal stimulation with PMA.
Another possibility of direct induction of NETs by aLf is 
also considered. It has been shown that Lf was expressed on the 
cell surface of primed neutrophils, and that aLf bound with cell 
surface Lf activated the neutrophils (18). Since the suboptimal 
dose of PMA (10 nM) induced cell surface expression of Lf (our 
unpublished results), aLf could activate neutrophils through 
interaction with the cell surface Lf resulting in enhancement 
of NET formation. Further studies are needed to reveal the 
mechanism of how aLf enhance the NET formation induced by a 
suboptimal dose of PMA.
Accumulating evidence indicates that excessive NET 
formation contributes directly to the dysfunction of vascular 
endothelial cells and results in the development of vasculopathy 
(19, 20). NET components, including MPO, which can mediate 
the generation of hypochlorite (OCl−) (21), histones (22), and 
matrix metalloproteinases (MMP), particularly MMP-2 and 
MMP-9 (23), have been demonstrated as strong effectors that 
induced vascular endothelial cell damage. In fact, the presence of 
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extracellular MPO and NET-related molecules, such as histones, 
has been shown in the glomerular lesions of AAV (10, 24, 25). In 
addition, the increase in expressions of both MMP-2 and MMP-9 
has been shown in the respiratory mucosa of EGPA patients (26). 
These reports correspond with our finding that the titer of aLf, 
which can contribute to enhancement of NET formation, is 
associated with the disease activity of EGPA.
Currently, it remains unrevealed which factors collaborate 
with aLf to induce NET formation in EGPA patients, as does 
PMA in the assay in vitro. Earlier studies have demonstrated that 
aLf could activate neutrophils primed by bacteria-derived f-Met–
Leu–Phe (fMLP) (18), but not by C5a or calcium ionophore 
(27). In addition, fMLP was shown to induce NET formation in 
neutrophils (28). It has been well-known that preceding infection 
often triggers the onset and recurrence of AAV, including EGPA. 
Accordingly, bacteria-derived fMLP can be a candidate for ally of 
aLf to induce NET formation in EGPA patients.
Among the three AAV types, including MPA, GPA, and 
EGPA, aLf were detected in the EGPA sera exclusively in this 
study. A  characteristic of EGPA is the presence of asthma or 
paranasal sinusitis history preceding the development of the 
disease. A recent study has demonstrated that a specific allergen 
for asthma induced Lf secretion from neutrophils derived from 
asthmatic patients (29). In asthma patients, however, ANCA, 
including aLf, are usually negative (30). Therefore, it is considered 
that the tolerance to Lf can be suspended with an undetermined 
reason resulting in the production of aLf in EGPA patients 
particularly. Although further studies are needed to clarify the 
mechanism of aLf production, the serum aLf can be a potential 
marker for the disease activity of some EGPA patients.
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